【摘要】 目的探讨阿尼西坦改善慢性精神分裂症患者认知功能的疗效。方法将64例慢性精神分裂症患者随机分为研究组32例和治疗组32例,分别予以奎的平(350±50)mg/d治疗8周,研究组同时合并阿尼西坦100mg/d,并于治疗前及治疗后分别进行阳性和阴性症状量表(PANSS)、简明精神状态量表(MMSE)、中国修订韦氏成人智力量表(WAIS-RC)、韦氏记忆量表(WMS)及威斯康星卡片分类测定(WCST)等评定,并与正常人组成的对照组进行比较。结果治疗前研究组和治疗组的MMSE、WMS及WAIS-RC均低于对照组,差异有显著性(P〈0.05),提示患者的认知功能有广泛性损害。治疗后研究组MMSE、WCST、WMS、WAIS-RC分数与治疗前比较差异有显著性(P〈0.05),而治疗后治疗组的WCST、WMS、WAIS-RC分数与治疗前比较无显著性差异(P〈0.05)。结论阿尼西坦改善慢性精神分裂症患者的认知功能疗效确切。更多还原

【Abstract】 Objective To study the curative effect of aniracetam on cognitive impairment in patients with chronic schizophrenia. Methods Sixty-four patients with chronic schizophrenia were randomly assigned to study group(n=32) and treatment group(n=32).Both groups were treated with quetiapine (350±50)mg/d for eight weeks,study group were treated with aniracetam (1000mg/d) simultaneoush.Both groups were measured with the Positive and Negative Symptom Scale(PANSS), the Wechsler Memory Scale(WMS),Mini-Mental State Examination(MMSE),Wechsler Adult Intelligence Scale (WAIS-RC) and Wisconsin Card Sorting Test (WCST).Results Before treatment,the scores of MMSE,WMS and WAIS-RC of both groups were significantly lower than those of normal controls(P0.05) .After treatment,scores of MMSE,WCST,WMS and WAIS-RC in study group had significant improvement,and those in treatment group were on the contrary. (P0.05).Conclusion Aniracetam may improve the cognitive function of chronic schizophenia.更多还原